Real-world adherence and persistence of dual antiplatelet therapy over two years in patients with coronary artery diseases

Dual antiplatelet therapy (DAPT) with acetylsalicylic acid (ASA)/clopidogrel showed a statistically significant better persistence vs ASA/ticagrelor and ASA/prasugrel. However, no statistically significant differences were seen in adherence to ASA/clopidogrel fixed dose combination (FDC) vs the use of two different pills.

Login to access this and all our premium content
New to Campus Sanofi? Register to access all our Content